COVID-19-associated encephalopathy

WikiDoc Resources for COVID-19-associated encephalopathy
Articles
Most recent articles on COVID-19-associated encephalopathy Most cited articles on COVID-19-associated encephalopathy Review articles on COVID-19-associated encephalopathy Articles on COVID-19-associated encephalopathy in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on COVID-19-associated encephalopathy Images of COVID-19-associated encephalopathy Photos of COVID-19-associated encephalopathy Podcasts & MP3s on COVID-19-associated encephalopathy Videos on COVID-19-associated encephalopathy
Evidence Based Medicine
Cochrane Collaboration on COVID-19-associated encephalopathy Bandolier on COVID-19-associated encephalopathy TRIP on COVID-19-associated encephalopathy
Clinical Trials
Ongoing Trials on COVID-19-associated encephalopathy at Clinical Trials.gov Trial results on COVID-19-associated encephalopathy Clinical Trials on COVID-19-associated encephalopathy at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on COVID-19-associated encephalopathy NICE Guidance on COVID-19-associated encephalopathy NHS PRODIGY Guidance FDA on COVID-19-associated encephalopathy CDC on COVID-19-associated encephalopathy
Books
Books on COVID-19-associated encephalopathy
News
COVID-19-associated encephalopathy in the news Be alerted to news on COVID-19-associated encephalopathy News trends on COVID-19-associated encephalopathy
Commentary
Blogs on COVID-19-associated encephalopathy
Definitions
Definitions of COVID-19-associated encephalopathy
Patient Resources / Community
Patient resources on COVID-19-associated encephalopathy Discussion groups on COVID-19-associated encephalopathy Patient Handouts on COVID-19-associated encephalopathy Directions to Hospitals Treating COVID-19-associated encephalopathy Risk calculators and risk factors for COVID-19-associated encephalopathy
Healthcare Provider Resources
Symptoms of COVID-19-associated encephalopathy Causes & Risk Factors for COVID-19-associated encephalopathy Diagnostic studies for COVID-19-associated encephalopathy Treatment of COVID-19-associated encephalopathy
Continuing Medical Education (CME)
CME Programs on COVID-19-associated encephalopathy
International
COVID-19-associated encephalopathy en Espanol COVID-19-associated encephalopathy en Francais
Business
COVID-19-associated encephalopathy in the Marketplace Patents on COVID-19-associated encephalopathy
Experimental / Informatics
List of terms related to COVID-19-associated encephalopathy

For COVID-19 frequently asked outpatient questions, click here.
For COVID-19 frequently asked inpatient questions, click here.
For COVID-19 patient information, click here.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Muhammad Adnan Haider, M.B.B.S.[2] Wajeeha Aiman, M.D.[3]

Synonyms and keywords:Encephalopathy in COVID-19, COVID-19 encephalopathy

Overview

Encephalopathy is an alteration of the level or contents of consciousness due to brain dysfunction and can result from global or focal brain lesions. SARS-CoV-2 which is the member of coronavirus family has caused many neurological complications including encephalopathy. Acute toxic encephalopathy is caused by toxemia, hypoxia and metabolic disorders due the systemic viral infection (viral sepsis).

Historical Perspective

COVID-19, a disease caused by SARS-CoV-2 first emerged in Wuhan, China in December 2019. It then spread so rapidly that it was declared as pandemic in Feb, 2020. It mostly presents with respiratory symptoms like flue, dry cough, fever, fatigue, dyspnea. Although rare but neurological manifestations have been reported throughout the spectrum of COVID-19 pandemic. These neurological symptoms range from headache, anosmia, meningitis, encephalitis, Guillain Berre Syndrome,and stroke. Encephalopathy is rare and few case has been reported with acute encephalopathy during the severe systemic SARS-CoV-2 infection.

Classification

• There is no established system for the classification of COVID-19-associated encephalopathy.
• On the basis of presentation, COVID-19-associated encephalopathy can be classified as acute.

Pathophysiology

• Severe COVID-19 infection can lead to dysfunction of multiple organs of the body that can lead to hypoxic or metabolic insults to brain and cause encephalopathy.
• Encephalitis/meningitis are caused by neurotropism of SARS-CoV-2 to brain and meninges through ACE2 receptors.
• Encephalopathy is caused by hyper inflammation of brain by following three mechanisms;

• cytokine storm
• Hypoxic brain injury
• molecular mimicry

Cytokine storm

• SARS-CoV-2 causes several neurological complications through production of inflammatory cytokines (mainly IL-6) from glial cells called cytokine storm syndrome.
• SARS-CoV-2 activates CD4 cells of the immune system and CD4 cells activate macrophages by producing granulocyte-macrophage colony stimulating factors. Actiavted macrophages now produce IL-6.
• IL-6 is a major cytokine of cytokine storm syndrome and leads to multiple organ failure. This severe organ damage leads to metabolic and toxic changes in the body which causes brain dysfunction and leads to SARS-CoV-2 related encephalopathy.
• This fact can be supported by the evidence that tocilizumab which is IL-6 antagonist is used in severe COVID-19 infections.

Hypoxic Brain Injury

• The hall mark of severe COVID-19 infection is dyspnea and hypoxemia due Acute Respiratory distress syndrome (ARDS).
• This hypoxia and hypoxemia is sometimes enough to cause diffuse brain injury and cause encephalopathy.

Molecular Mimicry

• Post-infectious encephalomyelitis, an autoimmune demyelinating disease of the brain, can be triggered by the SARS‐CoV‐2 virus.

• SARS-CoV-2 is considered to have similar antigenic determinants as that of some antigens present on human neuronal cells.
• Immunological response to the SARS‐CoV‐2 virus cross-react with the myelin autoantigens, resulting in post-infectious encephalomyelitis.
• Neuropathological findings confirmed vascular and demyelinating pathology in a patient who died from COVID-19.

Causes

• COVID-19-associated encephalopathy may be caused by SARS-CoV-2.
• To read more about this virus, click here.

Differentiating COVID-19-associated encephalopathy from other Diseases

• For further information about the differential diagnosis, click here.
• To view the differential diagnosis of COVID-19, click here.

Epidemiology and Demographics

• The incidence of COVID-19-associated encephalopathy is approximately 93 patients worldwide.
• In July 2020, the incidence of COVID-19-associated encephalopathy is approximately 93 cases with 69% of the patients in intensive care unit.
• Patients of all age groups may develop COVID-19-associated encephalopathy.
• The incidence of COVID-19-associated encephalopathy increases with age; the median age at diagnosis is 54 years.
• There is no racial predilection to COVID-19-associated encephalopathy but more cases were present in African Americans.
• COVID-19-associated encephalopathy affects men and women equally.

Risk Factors

• There are no established risk factors for COVID-19-associated encephalopathy.
• To view the risk factors of COVID-19, click here.

Screening

• There is insufficient evidence to recommend routine screening for COVID-19-associated encephalopathy.
• To view screening for COVID-19, click here.

Natural History, Complications, and Prognosis

• If left untreated, COVID-19-associated encephalopathy may cause long term neurological complications.
• To view Natural History for COVID-19, click here.

Complications

• Long term neurological complications can develop according to the involved brain parenchymal area.

Encephalopathy

Memory loss

Epilepsy

Personality changes

Hearing/vision loss

Coma/Death

Diagnosis

Diagnostic Study of Choice

• There are no established criteria for the diagnosis of COVID-19-associated encephalopathy.
• The diagnostic study of choice for COVID-19-associated encephalopathy is CSF analysis along with RT-PCR for SARS-CoV-2 positive on nasopharyngeal swab or on CSF.

Signs and symptoms

Common Symptoms

• These are the common presenting features:
  • Fever,
  • Shortness of breath
  • Headache,
  • Impaired consciousness
  • Cough
  • Fatigue

Less Common Symptoms

• There are few symptoms which are not present in all patients with COVID-19-associated encephalopathy:
  • Transient generalized seizure,
  • Absent brain reflexes,
  • Myoclonus,
  • Speech difficulty,
  • Choreiform movements,
  • Paralysis,
  • Dizziness,
  • Sedation,
  • Coma.

The COVID-19-associated encephalopathy cases have been analyzed in the table below:

Patient No.	Early symptoms	Later presentation	Lab. Findings	Specific Tests				Imaging studies
			CSF	bacterial panel	viral panel (VZV, CMV, HSV1, HSV2)	SARS-CoV-2		MRI/CT scan
						on nasopharyngeal sawab	on CSF
1. Poyiadji et.al reported a case report of a female in her late fifties who presented with COVID-19 associated acute hemorrhagic necrotizing encephalopathy	fever cough	altered mentation	Not possible due to traumatic rupture	Negative	Negative	RT-PCR for SARS-CoV-2 positive on nasopharyngeal swab	Negative	Noncontrast head CT images demonstrated symmetric hypoattenuation within the bilateral medial thalami with a normal CT angiogram and CT venogram Brain MRI demonstrated hemorrhagic rim enhancing lesions within the bilateral thalami, medial temporal lobes, and subinsular regions
2. A 74 year male who had traveled from Europe to USA was presented to emergency with COVID-19 related encephalopathy	Fever cough	headache altered mentationn	WBCs =4 RBCs = 0 Glucose 75 Proteins 68	Negative	Negative	positive	Negative	CT scan normal
3. 59 year female with history of aplastic anemia presented with COVID-19 related acute necrotizing encephalopathy involving brain stem. She returned from trip to Afghanistan	fever cough headache	seizure reduced consciousness flexion of upper limbs speech arrest	CSF opening pressure = 28 cm water Protein 2.3 WBCs= 4 cells	Negative	Negative	RT-PCR positive	Negative	MRI showed diffuse swelling and hemorrhage in the brain stem and both amygdalae
4. Benameur et. al reported a 31 year old african american presented with COVID-19 related encephalopathy.	fever dyspnea	ARDS and was intubated Comatosed post intubation absent brain reflexes	CSF opening pressure= 30 cm water proteins >200mg/dl WBCs 115 nucleated cells Glucose normal	Negative	Negative	RT-PCR positive for SARS-CoV-2	Negative	MRI howed nonenhancing cerebral edema and diffusion weighted imaging abnormalities predominantly involving the right cerebral hemisphere, as well as brain herniation
5.Benameur et. al reported a 34 year old african american with hypertension presented with COVID-19 related encephalopathy.	fever cough dyspnea	multiple myoclonus absent corneal and gag reflexes comatosed	CSF opening pressure= 48 cm of water no pleocytosis normal glucose mildly elevated proteins	Negative	Negative	positive RT-PCR for SARS-CoV-2	Negative	Brain MRI on day 15 showed a nonenhancing hyperintense lesion within the splenium of the corpus callosum
6. Benameur et. al reported a 64 year old african american with hypertension presented with COVID-19 related encephalopathy.	Fever Cough Dyspnea	profound encephalopathy absent with withdrawl to pain stimuli myoclonus absent deep tendon reflexes	Normal	Negative	Negative	RT-PCR positive for SARS-CoV-2	Negative	MRI showed an equivocal nonenhancing area of fluid-attenuated inversion recovery abnormality in the right temporal lobe.
7. Espinosa et. al presented a case report of COVID-19 related encephalopathy	Fever Dry cough	ARDS comatosed after he was off ventilator no response to painful stimuli decreased activity of brain on EEG	WBCs =2 cells proteins = 27 glucose = 68	Negative	Negative	Positive PCR for SARS-CoV-2	Negative	on MRI diffusion-weighted imaging shows an area of restricted diffusion in the left parietocoritcal region
8. Byrness et. al reported a case of 36 years old male who was suspected to have drug overdose but later was diagnosed with COVID-19 related encephalopathy	Presented with suspected drug overdose. urine screen positive for cocaine, opiates and benzodiazepenes	Fever 39.8 (2nd day) agitation choreiform movements of upper extremities	CSF findings negative for bacterial or viral meningitis/encephalitis	Negative	Negative	RT-PCR positive for SARS-CoV-2	Negative	(MRI) was obtained which demonstrated multiple focal enhancing lesions primarily affecting the bilateral medial putamen and left cerebellum
9. A 64 year old female presented with posterior reversible encephalopathy syndrome (PRES) and was reported by reported by Cariddi et. al	fever dyspnea	On 25th day of admission when she was weaned off sedation she had: blurred vision altered mentation left nasolabial fold was reduced reduced reflexes	CSF negative for bacterial or viral findings	Negative	negative	RT-PCR positive for SARS-CoV-2	negative	Brain CT and CTA were consistent with hemorrhagic Posterior Reversible Encephalopathy Syndrome On day 56 a brain MRI showed a reduction of the bilateral edema with bilateral occipital foci of subacute hemorrhage
10. A 48 year old male, ail pilot presented with hemorrhagic posterior reversible encephalopathy syndrome	fever dyspnea	High grade fever (2nd day) altered mentation ARDS	NA	Negative	negative	RT-PCR positive for SARS-CoV-2	negative	MRI showed vasogenic edema in the posterior parieto-occipital regions with subacute blood products suggestive of hemorrhagic posterior reversible encephalopathy syndrome (PRES)
11. Hayashi et.al reported the first case of COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion in 75-year-old male	Left dominant kinetic tremors walking instability urinary incontinence	fever day 2 Hypoxemia	NA	negative	negative	RT-PCR on throat swab positive for SARS-CoV-2	Negative	(MRI) of the brain revealed an abnormal hyperintensity in the splenium of corpus callosum (SCC), suspicious for clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS)
12. Cani et. al reported Frontal encephalopathy related to hyperinflammation in 77-year-old female with COVID-19	fever respiratory symptoms	Altered consciousness no goal directed activity myoclonus positive primitive reflexes	normal	negative	negative	SARS-CoV-2 positive on RT-PCR	Negative	MRI displayed diffuse white-matter lesions consistent with chronic small vessel disease without contrast enhancement
13. Encephalopathy and seizure activity in a 41-year-old COVID-19 well-controlled HIV patient was reported by Haddad S et.al	Fever fatigue chills cough	confusion agitation seizure EEG showed evidence of diffuse slowing but no epileptiform activity.	WBCs = 0 RBCs = 5 cells Proteins = 102 Glucose = 81	Negative	negative	SARS-CoV-2 positive on RT-PCR	neagtive	NA

Physical Examination

• Patients with COVID-19-associated encephalopathy usually appear confused.
• Physical examination of patients with COVID-19-associated encephalopathy is usually remarkable for altered mentation, speech arrest, seizure, and neurological illness.
• The presence of seizures, confusion, and neurological illnesses on physical examination is highly suggestive of COVID-19-associated encephalopathy.

Laboratory Findings

• Laboratory findings consistent with the diagnosis of COVID-19-associated encephalopathy include CSF analysis, RT-PCR for SARS-CoV-2 on nasopharyngeal swab and on CSF.
• RT-PCR for SARS-CoV-2 on CSF is usually normal among patients with COVID-19-associated encephalopathy.
• Some patients with COVID-19-associated encephalopathy may have reduced activity of brain on EEG, whih is usually suggestive of progression.

Electrocardiogram

• There are no ECG findings associated with COVID-19-associated encephalopathy.

X-ray

• There are no x-ray findings associated with COVID-19-associated encephalopathy.

• A Chest x-ray may be helpful in the diagnosis of COVID-19-associated respiratory disease.

Echocardiography or Ultrasound

• There are no echocardiography findings associated with COVID-19-associated encephalopathy.
• Echocardiography may be helpful in the diagnosis of COVID-19-associated cardiac disease.

CT scan

• Head CT scan may be helpful in the diagnosis of COVID-19-associated encephalopathy.
• Findings on head CT scan suggestive of COVID-19-associated encephalopathy include:
  • Noncontrast head CT images demonstrated symmetric hypoattenuation within the bilateral medial thalami with a normal CT angiogram and CT venogram,
  • Hemorrhagic Posterior Reversible Encephalopathy Syndrome.

MRI

• Brain MRI is helpful in the diagnosis of COVID-19-associated encephalopathy.
• Findings on brain MRI suggestive of COVID-19-associated encephalopathy include:
  • Hemorrhagic rim enhancing lesions within the bilateral thalami, medial temporal lobes, and subinsular regions,
  • Diffuse swelling and hemorrhage in the brain stem and both amygdalae,
  • Nonenhancing cerebral edema and diffusion weighted imaging abnormalities,
  • Brain herniation
  • Nonenhancing hyperintense lesion.

Other Imaging Findings

Other imaging studies may be helpful in the diagnosis of COVID-19-associated encephalopathy include:

• MR spectroscopy,
• CT angiogram and
• CT venogram may be helpful in the diagnosis of COVID-19-associated encephalopathy.

Other Diagnostic Studies

Other diagnostic studies for COVID-19-associated encephalopathy include:

• Antibody IgM for acute infection, and
• Antibody IgG for resolved or chronic infection.
• RT-PCR of SARS-CoV-2 RNA positive in CSF or nasopharyngeal swab.

Treatment

Medical Therapy

The mainstay of medical therapy for viral encephalitis are:

Symptomatic Treatment

• There is no specific treatment for COVID-19-associated encephalopathy; the mainstay of therapy is supportive care.
• Supportive therapy for COVID-19-associated encephalopathy includes corticosteroids, anti-epileptic drugs, and treating underlying condition.
• COVID-19-associated encephalopathy can present in a medical emergency and requires prompt treatment.
• Severe disease require intubation and mechanical ventilation.
• Anti-inflammatory medicines like pulse steroids (methylprednisolone 1,000 mg/day) are helpful in this disease, some patients improved even with a very low dose (60mg/day).
• Anti-epileptic drugs like levetiracetam (50-60 mg/kg/day) is necessary for seizure management in patients with refractory seizures.
• Tocilizumab (8mg/kg/dose) is IL-6 anatgonist, that reduces cytokine storm syndrome responsible for neurological manifestations in a COVID-19 patient.
• To see treatment protocol to manage the underlying cause i.e., COVID-19, click here

Surgery

• Surgical intervention is not recommended for the management of COVID-19-associated encephalopathy.
• Focal epileptic involvement of brain parenchyma can be treated with resection of the area.

Primary Prevention

• There are no established measures for the primary prevention of COVID-19-associated encephalopathy.
• To view primary prevention for COVID-19 click here.

Secondary Prevention

• There are no established measures for the secondary prevention of COVID-19-associated encephalopathy.
• To view secondary prevention for COVID-19 click here.

References

Template:WikiDoc Sources